Expression of Lamin A/C in early-stage breast cancer and its prognostic value

  • I. M. Alhudiri
  • C. C. Nolan
  • I. O. Ellis
  • A. Elzagheid
  • E. A. Rakha
  • Andrew R. Green
  • C. J. Chapman
Preclinical Study



Lamins A/C, a major component of the nuclear lamina, play key roles in maintaining nuclear integrity, regulation of gene expression, cell proliferation and apoptosis. Reduced lamin A/C expression in cancer has been reported to be a sign of poor prognosis. However, its clinical significance in breast cancer remains to be defined. This study aimed to evaluate expression and prognostic significance of lamin A/C in early-stage breast cancer.


Using immunohistochemical staining of tissue microarrays, expression of lamin A/C was evaluated in a large well-characterised series of early-stage operable breast cancer (n = 938) obtained from Nottingham Primary Breast Carcinoma Series. Association of lamin A/C expression with clinicopathological parameters and outcome was evaluated.


Positive expression rate of lamin A/C in breast cancer was 42.2% (n = 398). Reduced/loss of expression of lamin A/C was significantly associated with high histological grade (p < 0.001), larger tumour size (p = 0.004), poor Nottingham Prognostic Index score (p < 0.001), lymphovascular invasion (p = 0.014) and development of distant metastasis (p = 0.027). Survival analysis showed that reduced/loss of expression of lamin A/C was significantly associated with shorter breast cancer-specific survival (p = 0.008).


This study suggests lamin A/C plays a role in breast cancer and loss of its expression is associated with variables of poor prognosis and shorter outcome.


Breast cancer Lamin A/C Immunohistochemistry Tissue microarray Prognosis 



We thank the Nottingham Health Science Biobank and Breast Cancer Now Tissue Bank for the provision of tissue samples. The authors gratefully acknowledge the support of the Libyan Authority for Research, Science and Technology.

Compliance with ethical standards

Conflict of interest

Authors declare that they have no conflict of interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the Ethical Standards of the Institutional and/or National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Nottingham Research Ethics Committee 2 under the title “Development of a molecular genetic classification of breast cancer”.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Lammerding J, Fong LG, Ji JY et al (2006) Lamins a and C but not lamin B1 regulate nuclear mechanics. J Biol Chem 281:25768–25780. CrossRefGoogle Scholar
  2. 2.
    Butin-Israeli V, Adam SA, Goldman AE, Goldman RD (2012) Nuclear lamin functions and disease. Trends Genet 28:464–471. CrossRefGoogle Scholar
  3. 3.
    Kong L, Schäfer G, Bu H et al (2012) Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway. Carcinogenesis 33:751–759. CrossRefGoogle Scholar
  4. 4.
    Eckersley-Maslin MA, Bergmann JH, Lazar Z, Spector DL (2013) Lamin A/C is expressed in pluripotent mouse embryonic stem cells. Nucleus 4:53–60. CrossRefGoogle Scholar
  5. 5.
    Marmiroli S, Bertacchini J, Beretti F et al (2009) A-type lamins and signaling: the PI 3-kinase/Akt pathway moves forward. J Cell Physiol 220:553–561. CrossRefGoogle Scholar
  6. 6.
    Jung H, Lee J, Yang S et al (2013) Nuclear lamins in the brain—new insights into function and regulation. Mol Neurobiol 47:290–301. CrossRefGoogle Scholar
  7. 7.
    Gerace L, Comeau C, Benson M (1984) Organization and modulation of nuclear lamina structure. J Cell Sci Suppl 1:137–160CrossRefGoogle Scholar
  8. 8.
    Ivorra C, Kubicek M, González JM et al (2006) A mechanism of AP-1 suppression through interaction of c-Fos with lamin A/C. Genes Dev 20:307–320. CrossRefGoogle Scholar
  9. 9.
    Houben F, Willems CHMP, Declercq ILJ et al (2009) Disturbed nuclear orientation and cellular migration in A-type lamin deficient cells. Biochim Biophys Acta Mol Cell Res 1793:312–324. CrossRefGoogle Scholar
  10. 10.
    Ho CY, Jaalouk DE, Vartiainen MK, Lammerding J (2013) Lamin A/C and emerin regulate MKL1-SRF activity by modulating actin dynamics. Nature 497:507–513. CrossRefGoogle Scholar
  11. 11.
    Lee KK, Haraguchi T, Lee RS et al (2001) Distinct functional domains in emerin bind lamin A and DNA-bridging protein BAF. J Cell Sci 114:4567–4573Google Scholar
  12. 12.
    Worman HJ (2012) Nuclear lamins and laminopathies. J Pathol 226:316–325. CrossRefGoogle Scholar
  13. 13.
    Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410CrossRefGoogle Scholar
  14. 14.
    Zink D, Fische AH, Nickerson JA (2004) Nuclear structure in cancer cells. Nat Rev Cancer 4:677–687. CrossRefGoogle Scholar
  15. 15.
    Solovei I, Wang AS, Thanisch K et al (2013) LBR and lamin A/C sequentially tether peripheral heterochromatin and inversely regulate differentiation. Cell 152:584–598. CrossRefGoogle Scholar
  16. 16.
    Brachner A, Foisner R (2014) Lamina-associated polypeptide (LAP)2α and other LEM proteins in cancer biology. Adv Exp Med Biol 773:143–163. CrossRefGoogle Scholar
  17. 17.
    Qi Y-X, Yao Q-P, Huang K et al (2016) Nuclear envelope proteins modulate proliferation of vascular smooth muscle cells during cyclic stretch application. Proc Natl Acad Sci USA 113:5293–5298. CrossRefGoogle Scholar
  18. 18.
    Markiewicz E, Dechat T, Foisner R et al (2002) Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of retinoblastoma protein. Mol Biol Cell 13:4401–4413. CrossRefGoogle Scholar
  19. 19.
    Lin F, Worman HJ (1993) Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem 268:16321–16326Google Scholar
  20. 20.
    Tilli CM, Ramaekers FC, Broers JL et al (2003) Lamin expression in normal human skin, actinic keratosis, squamous cell carcinoma and basal cell carcinoma. Br J Dermatol 148:102–109CrossRefGoogle Scholar
  21. 21.
    Broers JL, Raymond Y, Rot MK et al (1993) Nuclear A-type lamins are differentially expressed in human lung cancer subtypes. Am J Pathol 143:211–220Google Scholar
  22. 22.
    Kaspi E, Frankel D, Guinde J et al (2017) Low lamin A expression in lung adenocarcinoma cells from pleural effusions is a pejorative factor associated with high number of metastatic sites and poor performance status. PLoS ONE 12:e0183136. CrossRefGoogle Scholar
  23. 23.
    Moss SF, Krivosheyev V, de Souza A et al (1999) Decreased and aberrant nuclear lamin expression in gastrointestinal tract neoplasms. Gut 45:723–729CrossRefGoogle Scholar
  24. 24.
    Prokocimer M, Margalit A, Gruenbaum Y (2006) The nuclear lamina and its proposed roles in tumorigenesis: projection on the hematologic malignancies and future targeted therapy. J Struct Biol 155:351–360. CrossRefGoogle Scholar
  25. 25.
    Wu Z, Wu L, Weng D et al (2009) Reduced expression of lamin A/C correlates with poor histological differentiation and prognosis in primary gastric carcinoma. J Exp Clin Cancer Res 28:8. CrossRefGoogle Scholar
  26. 26.
    Belt EJT, Fijneman RJA, van den Berg EG et al (2011) Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence. Eur J Cancer 47:1837–1845. CrossRefGoogle Scholar
  27. 27.
    Wazir U, Ahmed M, Bridger J et al (2013) The clinicopathological significance of lamin A/C, lamin B1 and lamin B receptor mRNA expression in human breast cancer. Cell Mol Biol Lett 18:595–611. CrossRefGoogle Scholar
  28. 28.
    Matsumoto A, Hieda M, Yokoyama Y et al (2015) Global loss of a nuclear lamina component, lamin A/C, and LINC complex components SUN1, SUN2, and nesprin-2 in breast cancer. Cancer Med 4:1547–1557. CrossRefGoogle Scholar
  29. 29.
    Capo-chichi CD, Cai KQ, Smedberg J et al (2011) Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer. Chin J Cancer 30:415–425CrossRefGoogle Scholar
  30. 30.
    Aljada A, Doria J, Saleh AM et al (2016) Altered Lamin A/C splice variant expression as a possible diagnostic marker in breast cancer. Cell Oncol 39:161–174. CrossRefGoogle Scholar
  31. 31.
    Abd El-Rehim DM, Ball G, Pinder SE et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350. CrossRefGoogle Scholar
  32. 32.
    Kollias J, Murphy CA, Elston CW et al (1999) The prognosis of small primary breast cancers. Eur J Cancer 35:908–912CrossRefGoogle Scholar
  33. 33.
    Madjd Z, Pinder SE, Paish C et al (2003) Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol 200:633–639. CrossRefGoogle Scholar
  34. 34.
    Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252–7259CrossRefGoogle Scholar
  35. 35.
    Agrelo R, Setien F, Espada J et al (2005) Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. J Clin Oncol 23:3940–3947. CrossRefGoogle Scholar
  36. 36.
    Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163–167. CrossRefGoogle Scholar
  37. 37.
    Baylin SB, Esteller M, Rountree MR et al (2001) Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10:687–692CrossRefGoogle Scholar
  38. 38.
    Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21:5462–5482. CrossRefGoogle Scholar
  39. 39.
    Yan PS, Venkataramu C, Ibrahim A et al (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12:6626–6636. CrossRefGoogle Scholar
  40. 40.
    Cheng ASL, Culhane AC, Chan MWY et al (2008) Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res 68:1786–1796. CrossRefGoogle Scholar
  41. 41.
    Sunami E, Shinozaki M, Sim MS et al (2008) Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 10:R46. CrossRefGoogle Scholar
  42. 42.
    Jing F, Yuping W, Yong C et al (2010) CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol 31:321–331. CrossRefGoogle Scholar
  43. 43.
    Karray-Chouayekh S, Trifa F, Khabir A et al (2010) Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients. J Cancer Res Clin Oncol 136:203–210. CrossRefGoogle Scholar
  44. 44.
    Sharma G, Mirza S, Parshad R et al (2010) Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci 87:83–91. CrossRefGoogle Scholar
  45. 45.
    Swift-Scanlan T, Vang R, Blackford A et al (2011) Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol Ther 11:853–865CrossRefGoogle Scholar
  46. 46.
    Irianto J, Pfeifer CR, Ivanovska IL et al (2016) Nuclear lamins in cancer. Cell Mol Bioeng 9:258–267. CrossRefGoogle Scholar
  47. 47.
    Ferguson AT, Lapidus RG, Baylin SB, Davidson NE (1995) Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55:2279–2283Google Scholar
  48. 48.
  49. 49.
    Tommasi S, Karm DL, Wu X et al (2009) Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res 11:R14. CrossRefGoogle Scholar
  50. 50.
    Yang L, Guan T, Gerace L (1997) Lamin-binding fragment of LAP2 inhibits increase in nuclear volume during the cell cycle and progression into S phase. J Cell Biol 139:1077–1087CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Breast SurgeryThe University of NottinghamNottinghamUK
  2. 2.Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, Nottingham City HospitalThe University of NottinghamNottinghamUK
  3. 3.Genetic Engineering DepartmentBiotechnology Research CentreTripoliLibya

Personalised recommendations